ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential

As previously reported, BTIG initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $45 price target The late-stage oncology company is developing firmonertinib, which is approved in China and has accumulated extensive real-world and clinical experience, while updated data from the global Phase 1b FURTHER study demonstrate “a best-in-class profile” in first-line PACC NSCLC with 68.2% confirmed ORR and 16.0-month PFS, the analyst tells investors. The pivotal global Phase 3 FURVENT trial is now guided to read out in early 2026 following slower-than-expected event accumulation, notes the analyst, who models combined global risk-unadjusted peak sales of greater than $1B for firmonertinib.